Drug Trial Radar · NCT03936777
A Study to Investigate the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
412
Actual
Start
Apr 22, 2019
Primary completion
May 8, 2025
Study completion May 8, 2025
Sponsor
- Lead sponsor
- Zogenix, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
- First posted
- May 3, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an international, multicenter, open-label, long-term safety study of ZX008 in subjects with Dravet syndrome, Lennox-Gastaut syndrome or epileptic encephalopathy
Conditions
- Dravet Syndrome
- Lennox Gastaut Syndrome
- Epileptic Encephalopathy
Interventions
ZX008 (Fenfluramine Hydrochloride)Drug
Fenfluramine hydrochloride provided in a concentration of 2.5 mg/mL.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: From First dose of ZX008 (in study EP0215 [ZX008-1900]) to Cardiac Follow-up after ZX008 treatment (Up to 6 Years, 17 Days)
Locations
71 sites in 14 countries. Site status is shown where the registry gives one.
Ep0215 107
Tucson, Arizona
Ep0215 144
Los Angeles, California
Ep0215 108
San Diego, California
Ep0215 101
San Francisco, California
Ep0215 103
Aurora, Colorado
Ep0215 115
Gulf Breeze, Florida
Ep0215 104
Miami, Florida
Ep0215 141
Orlando, Florida
Ep0215 121
Winter Park, Florida
Ep0215 117
Atlanta, Georgia
Ep0215 110
Chicago, Illinois
Ep0215 140
Bethesda, Maryland
Ep0215 112
Boston, Massachusetts
Ep0215 109
Rochester, Minnesota
Ep0215 132
Roseville, Minnesota
Ep0215 105
Hackensack, New Jersey
Ep0215 118
Livingston, New Jersey
Ep0215 150
Hawthorne, New York
Ep0215 142
New York, New York
Ep0215 131
Cleveland, Ohio
Ep0215 124
Memphis, Tennessee
Ep0215 146
Dallas, Texas
Ep0215 126
Fort Worth, Texas
Ep0215 106
Salt Lake City, Utah
Ep0215 119
Seattle, Washington
Ep0215 125
Tacoma, Washington
Ep0215 301
Heidelberg, Australia
Ep0215 302
South Brisbane, Australia
Ep0215 303
Westmead, Australia
Ep0215 803
Brussels, Belgium
Ep0215 801
Edegem, Belgium
Ep0215 802
Jette, Belgium
Ep0215 202
Montreal, Canada
Ep0215 204
Toronto, Canada
Ep0215 201
Vancouver, Canada
Ep0215 701
Dianalund, Denmark
Ep0215 1004
Bordeaux, France
Ep0215 1005
Lille, France
Ep0215 1007
Marseille, France
Ep0215 1001
Paris, France
Showing 40 of 71 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.